Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 24 phantom stock units linked to Pfizer common stock on 11/14/2025 at $25.06 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service, rather than in actual shares. The units may be transferred by him into an alternative investment account at any time. Following this transaction, he beneficially owned 743,548 derivative securities in the form of these phantom stock units, held in direct form.
Pfizer Inc. filed a Form 13F reporting holdings: 24 instrument entries with a total value of $437,450,705. The report was signed on 11-13-2025. This filing lists institutional equity positions held by the manager as of the reporting period and summarizes aggregate value and count of entries.
Pfizer Inc. completed its acquisition of Metsera, Inc. The deal converted each Metsera share into $65.60 in cash at closing, representing an enterprise value of approximately $7.0 billion, plus a non-transferable contingent value right (CVR) worth up to $20.65 per share upon achieving specified milestones.
The CVR includes three potential cash payments tied to Metsera’s GLP‑1 programs:
- $4.60 per share upon initiation of the Phase 3 clinical trial of the MET-097i (GLP-1 receptor antagonist) + MET-233i (amylin analog) combination.
- $6.40 per share upon FDA approval of monthly MET-097i monotherapy.
- $9.65 per share upon FDA approval of monthly MET-097i + MET-233i combination.
Pfizer Inc. filed its Q3 2025 report, showing lower quarterly results versus last year and executing major portfolio moves. Total revenues were $16,654 million, down from $17,702 million in Q3 2024, and diluted EPS was $0.62 versus $0.78. Year-to-date, net income attributable to common shareholders was $9,419 million, up from $7,621 million, aided by a negative effective tax rate and portfolio actions.
The company recorded a $1,350 million charge in Acquired in-process R&D tied to an exclusive global (ex-China) in-licensing of SSGJ-707 from 3SBio, which also included a $100 million equity investment and up to $4,800 million in potential milestones. Pfizer also entered R&D funding arrangements with Abingworth (up to $200 million through 2027) and Blackstone (up to $326 million through 2028), with approval- and sales-based milestone payment structures after potential approvals.
Pfizer continued multi-year cost programs: the Realigning Our Cost Base Program and the Manufacturing Optimization Program. Cumulative costs through September 28, 2025 reached $3.7 billion for the realignment and $1.0 billion for manufacturing optimization. Cash from investing included $6,311 million of proceeds from sales of the remaining Haleon stake. Shares outstanding were 5,685,707,552 as of October 29, 2025.
Pfizer Inc. filed an 8-K announcing its third-quarter 2025 financial results. The company furnished a press release as Exhibit 99 dated November 4, 2025, detailing the quarter’s performance. The information under Item 2.02 (Results of Operations and Financial Condition) is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except by specific reference. An Inline XBRL cover page file is also included as Exhibit 104.
Pfizer Inc. (PFE) insider activity: Chairman & CEO and Director Albert Bourla reported the acquisition of 24 phantom stock units on 10/31/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
The filing lists a price of $24.65 for the derivative security and shows 731,108 derivative securities beneficially owned following the transaction, held as direct ownership. These phantom stock units represent the value of one share each and are settled in cash after the reporting person’s separation from service; they may be moved into an alternative investment account at any time.
Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.
Pfizer Inc. (PFE) Chairman & CEO Albert Bourla reported acquiring 83 phantom stock units on 10/14/2025 at a derivative security price of $24.52. Following this transaction, he beneficially owns 731,058 derivative securities. Each unit represents one share of common stock and was acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, with settlement in cash after separation from service.
Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.
Joseph J. Echevarria, a Director of Pfizer Inc. (PFE), reported an acquisition on 09/30/2025 of 1,815.149 phantom stock units that represent deferred director compensation. The filing shows these units were recorded as acquired with a per-share reference price of $25.48 and that 1,815.149 underlying common shares correspond to the units.
The form states these phantom units are deferred compensation that will be settled in cash or common stock at the director's election following the reporting person’s retirement from the Board. After the reported transaction the filing lists 144,989.542 common shares as beneficially owned. The form was signed by an attorney on behalf of Mr. Echevarria on 10/02/2025.